新京报贝壳财经讯1月6日，爱朋医疗（300753）公告，公司股票交易价格于2026年1月5日、2026年1月6 日连续两个交易日内收盘价格涨幅偏离值累计超过30%。公司前期披露的信息不存在需要更正、补充之 处；公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公开重大信 息；公司近期经营情况正常，内外部经营环境未发生重大变化；公司、控股股东及实际控制人不存在关 于本公司的应披露而未披露的重大事项，或处于筹划阶段的重大事项；公司控股股东、实际控制人在股 票异常波动期间不存在买卖公司股票情形。 ...

证券日报网讯 1月6日，爱朋医疗（300753）发布公告称，公司股票于2026年1月5日、6日连续两个交易 日收盘涨幅偏离值累计超30%，属异常波动。公司核查后称前期披露无需更正，经营正常，无未披露重 大事项，控股股东及实控人期间未买卖股票。 ...

爱朋医疗公告，公司股票交易价格于2026年1月5日、2026年1月6日连续两个交易日内收盘价格涨幅偏离 值累计超过30%。公司前期披露的信息不存在需要更正、补充之处；公司未发现近期公共传媒报道了可 能或已经对本公司股票交易价格产生较大影响的未公开重大信息；公司近期经营情况正常，内外部经营 环境未发生重大变化；公司、控股股东及实际控制人不存在关于本公司的应披露而未披露的重大事项， 或处于筹划阶段的重大事项；公司控股股东、实际控制人在股票异常波动期间不存在买卖公司股票情 形。 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2026-001 江苏爱朋医疗科技股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3、公司近期经营情况正常，内外部经营环境未发生重大变化； 4、公司、控股股东及实际控制人不存在关于本公司的应披露而未披露的重大事 项，或处于筹划阶段的重大事项； 5、公司控股股东、实际控制人在股票异常波动期间不存在买卖公司股票情形。 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没有任何根据《深圳证券交易所创业板股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等； 董事会也未获悉公司有根据《深圳证券交易所创业板股票上市规则》等有关规定应予 以披露而未披露的、对公司股票及其衍生品种交易价格产生较大影响的信息；公司前 期披露的信息不存在需要更正、补充之处。 四、风 ...

从资金流向上来看，当日医疗器械板块主力资金净流出13.5亿元，游资资金净流入4.26亿元，散户资金净 流入9.24亿元。医疗器械板块个股资金流向见下表： 证券之星消息，1月6日医疗器械板块较上一交易日上涨1.43%，伟思医疗领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688580 | 伟恩医疗 | 69.70 | 20.01% | 10.29万 | | 6.98 亿 | | 688626 | 翔宇医疗 | 87.12 | 20.00% | 8.63万 | | 7.42亿 | | 300753 | 爰朋医疗 | 39.96 | 20.00% | 15.74万 | | 6.19亿 | | 301363 | 美好医疗 | 34.63 | 19.99% | - 3.91万 | | 1.36亿 | | 688273 | 麦澜德 | 61.22 | 19.9 ...

Core Insights - The market experienced a strong performance with 120 stocks hitting the daily limit up, and a total of 43 stocks classified as consecutive limit-up stocks, indicating a bullish sentiment among investors [1] - The advancement rate of consecutive limit-up stocks reached 71.42%, excluding ST and delisted stocks, showcasing a significant increase in market enthusiasm [1] Group 1: Market Performance - Over 4,100 stocks rose in the market, with more than 100 stocks hitting the limit up for the second consecutive trading day [1] - The stock of Victory Energy, which resumed trading, achieved a limit up with a T-shaped pattern, marking its 13th consecutive limit-up [1] - Jia Mei Packaging, which underwent a shareholding change, also saw a limit up, achieving 12 limit-ups over 16 days [1] Group 2: Sector Performance - Resource stocks, particularly in non-ferrous metals and chemicals, showed strong performance, with Luoyang Molybdenum and Zijin Mining both rising over 6% to reach historical highs [1] - Hengli Petrochemical has increased over 20% since December, reaching a nearly four-year high [1] Group 3: Emerging Concepts - The brain-computer interface sector continued its strong momentum, with nearly 20 stocks achieving consecutive limit-ups, including Sanbo Brain Science, Meihao Medical, and Aipeng Medical [1] - The commercial aerospace concept remained active, with notable performances from large-cap stocks such as China Satellite Communications, which achieved 4 limit-ups in 6 days, and Goldwind Technology, which hit a limit up and reached a historical high [1]

6日，A股三大指数高开，截至9：50左右，沪指报4054.25点，突破2025年11月14日的阶段高点，刷新2015年7月底以来的新高。 | 上证指数 | 深证成指 | 科创综指 | | --- | --- | --- | | 4054.25 | 13946.42 | 1723.70 | | +30.83 +0.77% +117.79 +0.85% +27.86 +1.64% | | | | 万得全A | 创业板指 | 北证50 | | 6599.79 | 3318.62 | 1482.88 | | +61.85 +0.95% +24.07 +0.73% +16.46 +1.12% | | | | 沪深300 | 中证500 | 中证A500 | | 4762.71 | 7745.80 | 5823.89 | | +44.97 +0.95% | +94.61 +1.24% +60.59 +1.05% | | | 中证1000 | 深证100 | 中证红利 | | 7818.17 | 5966.20 | 5538.87 | | +64.29 +0.83% | +37.87 +0.64% | +13.75 +0. ...

创新医疗、倍益康、三博脑科、南京熊猫、美好医疗涨停，熵基科技涨超15%，麦澜德、爱朋医疗涨超 10%。 (本文来自第一财经) ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The brain-computer interface (BCI) technology is undergoing a period of accelerated transformation, with various technical paths available, including invasive, semi-invasive, and non-invasive methods, each with its own advantages in signal quality, safety, and operational difficulty [5][19] - The Chinese brain-computer interface market is projected to grow significantly, with the market size reaching approximately 1.73 billion yuan in 2023, accounting for 12.5% of the global market [6] - The industry is supported by a three-pronged policy approach focusing on planning, payment, and standards, which is expected to facilitate rapid development [6][33] Summary by Sections 1. Brain-Computer Interface Overview - BCI is a multidisciplinary technology that integrates neuroscience, computer science, and engineering to enable communication between the brain and external devices [17] - The technology operates through a closed-loop system involving signal input, processing, device control, and feedback [17] 2. Policy Support for BCI Development - The Chinese government has issued several policies to support the BCI industry, including the "Implementation Opinions on Promoting the Innovation and Development of the Brain-Computer Interface Industry" which outlines goals for 2027 and 2030 [6][43] - The policies aim to establish a robust industrial ecosystem, enhance innovation capabilities, and promote clinical applications of BCI technologies [43][44] 3. Technological Advancements and Applications - Core technological breakthroughs are occurring in the upstream segment of the BCI industry, particularly in hardware such as electrodes and chips [7] - The medical application of BCI is predominant, with 56% of the market share in 2023, focusing on various therapeutic areas including cognitive disorders and movement disabilities [7][9] - Companies like Lepu Medical and Aipeng Medical are actively involved in developing deep brain stimulation (DBS) technologies, with some preparing for IPOs [7][8] 4. Investment Recommendations - The report suggests focusing on both invasive and non-invasive BCI products, with specific companies identified as beneficiaries based on their clinical trial progress and commercialization potential [8] - Notable companies include Aipeng Medical and Lepu Medical for invasive products, and Xiangyu Medical and Innovation Medical for non-invasive products [8]

Market Overview - The Shanghai Composite Index (沪指) reached 4057 points, breaking the previous high from November 14, 2025, and marking the highest level since July 2015 [1] - The index has achieved a record of 12 consecutive daily gains, the longest since 1993, with the previous record being 11 consecutive gains [7] Sector Performance - The healthcare sector, particularly companies involved in brain-computer interfaces, saw significant gains with Xiangyu Medical (翔宇医疗) and Aipeng Medical (爱朋医疗) hitting the 20% daily limit up [2][3] - Solid-state battery stocks experienced a surge, with companies like Pulit (普利特) and Jinlongyu (金龙羽) reaching their daily limit up, while others like Aotwei (奥特维) and Daoshi Technology (道氏技术) rose over 10% [3][5] Investment Insights - The solid-state battery market is projected to see demand exceed 150 GWh by 2030, with companies like Donut Lab announcing the first commercially viable solid-state battery at the CES 2026 [6] - Investment recommendations focus on equipment manufacturers capable of complete line delivery and those benefiting from process improvements in solid-state battery production [6]